July 26, 2011
GlaxoSmithKline CEO and CFO Interviewed on Q2 2011 Results
LONDON, July 26, 2011 /PRNewswire/ --
UK pharma group GlaxoSmithKline reports a 2% sales dip in the second
quarter but highlights strong underlying sales momentum.
CEO Andrew Witty and CFO Simon Dingemans review Q2 results including overall
delivery of strategy, declining "headwinds", R&D strategy, improving margins
and a review of the recently implemented Drug Performance Units.
The interview and transcript are available now on
Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company executives. If
you would like to contact us, please email [email protected] or